

Peter B Dirks

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/343923/publications.pdf>

Version: 2024-02-01

157
papers

27,802
citations

22099

59
h-index

12558

132
g-index

172
all docs

172
docs citations

172
times ranked

32010
citing authors

#	ARTICLE	IF	CITATIONS
1	Identification of human brain tumour initiating cells. <i>Nature</i> , 2004, 432, 396-401.	13.7	6,758
2	Identification of a cancer stem cell in human brain tumors. <i>Cancer Research</i> , 2003, 63, 5821-8.	0.4	3,675
3	High-Resolution CRISPR Screens Reveal Fitness Genes and Genotype-Specific Cancer Liabilities. <i>Cell</i> , 2015, 163, 1515-1526.	13.5	1,339
4	Cancer stem cells: an evolving concept. <i>Nature Reviews Cancer</i> , 2012, 12, 133-143.	12.8	1,055
5	Glioma Stem Cell Lines Expanded in Adherent Culture Have Tumor-Specific Phenotypes and Are Suitable for Chemical and Genetic Screens. <i>Cell Stem Cell</i> , 2009, 4, 568-580.	5.2	881
6	Intertumoral Heterogeneity within Medulloblastoma Subgroups. <i>Cancer Cell</i> , 2017, 31, 737-754.e6.	7.7	836
7	Subgroup-specific structural variation across 1,000 medulloblastoma genomes. <i>Nature</i> , 2012, 488, 49-56.	13.7	761
8	Tumour-initiating cells: challenges and opportunities for anticancer drug discovery. <i>Nature Reviews Drug Discovery</i> , 2009, 8, 806-823.	21.5	755
9	Immune Checkpoint Inhibition for Hypermutant Glioblastoma Multiforme Resulting From Germline Biallelic Mismatch Repair Deficiency. <i>Journal of Clinical Oncology</i> , 2016, 34, 2206-2211.	0.8	692
10	Cancer stem cells in nervous system tumors. <i>Oncogene</i> , 2004, 23, 7267-7273.	2.6	670
11	Comprehensive Analysis of Hypermutation in Human Cancer. <i>Cell</i> , 2017, 171, 1042-1056.e10.	13.5	596
12	Single cell-derived clonal analysis of human glioblastoma links functional and genomic heterogeneity. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2015, 112, 851-856.	3.3	321
13	Fate mapping of human glioblastoma reveals an invariant stem cell hierarchy. <i>Nature</i> , 2017, 549, 227-232.	13.7	321
14	Combined hereditary and somatic mutations of replication error repair genes result in rapid onset of ultra-hypermutated cancers. <i>Nature Genetics</i> , 2015, 47, 257-262.	9.4	306
15	Childhood cerebellar tumours mirror conserved fetal transcriptional programs. <i>Nature</i> , 2019, 572, 67-73.	13.7	293
16	Prognostic value of medulloblastoma extent of resection after accounting for molecular subgroup: a retrospective integrated clinical and molecular analysis. <i>Lancet Oncology</i> , The, 2016, 17, 484-495.	5.1	274
17	The current consensus on the clinical management of intracranial ependymoma and its distinct molecular variants. <i>Acta Neuropathologica</i> , 2017, 133, 5-12.	3.9	271
18	Divergent clonal selection dominates medulloblastoma at recurrence. <i>Nature</i> , 2016, 529, 351-357.	13.7	266

#	ARTICLE	IF	CITATIONS
19	<i>BRAF</i> Mutation and <i>CDKN2A</i> Deletion Define a Clinically Distinct Subgroup of Childhood Secondary High-Grade Glioma. <i>Journal of Clinical Oncology</i> , 2015, 33, 1015-1022.	0.8	244
20	Integrated Molecular and Clinical Analysis of 1,000 Pediatric Low-Grade Gliomas. <i>Cancer Cell</i> , 2020, 37, 569-583.e5.	7.7	244
21	Quiescent Sox2+ Cells Drive Hierarchical Growth and Relapse in Sonic Hedgehog Subgroup Medulloblastoma. <i>Cancer Cell</i> , 2014, 26, 33-47.	7.7	241
22	A Feedforward Mechanism Mediated by Mechanosensitive Ion Channel PIEZO1 and Tissue Mechanics Promotes Glioma Aggression. <i>Neuron</i> , 2018, 100, 799-815.e7.	3.8	241
23	Therapeutic and Prognostic Implications of BRAF V600E in Pediatric Low-Grade Gliomas. <i>Journal of Clinical Oncology</i> , 2017, 35, 2934-2941.	0.8	232
24	Frequent Amplification of a chr19q13.41 MicroRNA Polycistron in Aggressive Primitive Neuroectodermal Brain Tumors. <i>Cancer Cell</i> , 2009, 16, 533-546.	7.7	207
25	Functional Enhancers Shape Extrachromosomal Oncogene Amplifications. <i>Cell</i> , 2019, 179, 1330-1341.e13.	13.5	206
26	Integrated (epi)-Genomic Analyses Identify Subgroup-Specific Therapeutic Targets in CNS Rhabdoid Tumors. <i>Cancer Cell</i> , 2016, 30, 891-908.	7.7	191
27	Roadmap for the Emerging Field of Cancer Neuroscience. <i>Cell</i> , 2020, 181, 219-222.	13.5	182
28	Therapeutic targeting of ependymoma as informed by oncogenic enhancer profiling. <i>Nature</i> , 2018, 553, 101-105.	13.7	170
29	Inhibition of Dopamine Receptor D4 Impedes Autophagic Flux, Proliferation, and Survival of Glioblastoma Stem Cells. <i>Cancer Cell</i> , 2016, 29, 859-873.	7.7	169
30	Fusion of TTYH1 with the C19MC microRNA cluster drives expression of a brain-specific DNMT3B isoform in the embryonal brain tumor ETMR. <i>Nature Genetics</i> , 2014, 46, 39-44.	9.4	167
31	Multipotent CD15+ Cancer Stem Cells in <i>Patched-1</i> Deficient Mouse Medulloblastoma. <i>Cancer Research</i> , 2009, 69, 4682-4690.	0.4	166
32	Brain Tumor Stem Cells: Bringing Order to the Chaos of Brain Cancer. <i>Journal of Clinical Oncology</i> , 2008, 26, 2916-2924.	0.8	164
33	Therapeutic Impact of Cytoreductive Surgery and Irradiation of Posterior Fossa Ependymoma in the Molecular Era: A Retrospective Multicohort Analysis. <i>Journal of Clinical Oncology</i> , 2016, 34, 2468-2477.	0.8	160
34	Chemical genetics reveals a complex functional ground state of neural stem cells. <i>Nature Chemical Biology</i> , 2007, 3, 268-273.	3.9	153
35	ASCL1 Reorganizes Chromatin to Direct Neuronal Fate and Suppress Tumorigenicity of Glioblastoma Stem Cells. <i>Cell Stem Cell</i> , 2017, 21, 209-224.e7.	5.2	150
36	Molecular subgroups of atypical teratoid rhabdoid tumours in children: an integrated genomic and clinicopathological analysis. <i>Lancet Oncology</i> , The, 2015, 16, 569-582.	5.1	147

#	ARTICLE	IF	CITATIONS
37	Gradient of Developmental and Injury Response transcriptional states defines functional vulnerabilities underpinning glioblastoma heterogeneity. <i>Nature Cancer</i> , 2021, 2, 157-173.	5.7	147
38	TERT promoter mutations are highly recurrent in SHH subgroup medulloblastoma. <i>Acta Neuropathologica</i> , 2013, 126, 917-929.	3.9	146
39	Pervasive H3K27 Acetylation Leads to ERV Expression and a Therapeutic Vulnerability in H3K27M Gliomas. <i>Cancer Cell</i> , 2019, 35, 782-797.e8.	7.7	143
40	Genome-Wide CRISPR-Cas9 Screens Expose Genetic Vulnerabilities and Mechanisms of Temozolomide Sensitivity in Glioblastoma Stem Cells. <i>Cell Reports</i> , 2019, 27, 971-986.e9.	2.9	139
41	Cancer Stem Cells: At the Headwaters of Tumor Development. <i>Annual Review of Pathology: Mechanisms of Disease</i> , 2007, 2, 175-189.	9.6	136
42	Stalled developmental programs at the root of pediatric brain tumors. <i>Nature Genetics</i> , 2019, 51, 1702-1713.	9.4	136
43	DNA hypermethylation within TERT promoter upregulates TERT expression in cancer. <i>Journal of Clinical Investigation</i> , 2018, 129, 223-229.	3.9	130
44	GLUT1 inhibition blocks growth of RB1-positive triple negative breast cancer. <i>Nature Communications</i> , 2020, 11, 4205.	5.8	130
45	Brain tumor stem cells: The cancer stem cell hypothesis writ large. <i>Molecular Oncology</i> , 2010, 4, 420-430.	2.1	127
46	Activity of the Retinoblastoma Family Proteins, pRB, p107, and p130, during Cellular Proliferation and Differentiation. <i>Critical Reviews in Biochemistry and Molecular Biology</i> , 1996, 31, 237-271.	2.3	117
47	Supratentorial primitive neuroectodermal tumors in children. <i>Journal of Neuro-Oncology</i> , 1996, 29, 75-84.	1.4	114
48	Spatial heterogeneity in medulloblastoma. <i>Nature Genetics</i> , 2017, 49, 780-788.	9.4	112
49	MLL5 Orchestrates a Cancer Self-Renewal State by Repressing the Histone Variant H3.3 and Globally Reorganizing Chromatin. <i>Cancer Cell</i> , 2015, 28, 715-729.	7.7	90
50	A Hematogenous Route for Medulloblastoma Leptomeningeal Metastases. <i>Cell</i> , 2018, 172, 1050-1062.e14.	13.5	85
51	Coexpression of nestin and vimentin intermediate filaments in invasive human astrocytoma cells. <i>International Journal of Developmental Neuroscience</i> , 1999, 17, 503-515.	0.7	79
52	Metabolic Regulation of the Epigenome Drives Lethal Infantile Ependymoma. <i>Cell</i> , 2020, 181, 1329-1345.e24.	13.5	79
53	A Tumorigenic MLL-Homeobox Network in Human Glioblastoma Stem Cells. <i>Cancer Research</i> , 2013, 73, 417-427.	0.4	77
54	PRMT5 inhibition disrupts splicing and stemness in glioblastoma. <i>Nature Communications</i> , 2021, 12, 979.	5.8	77

#	ARTICLE	IF	CITATIONS
55	The INK4A/ARF locus: role in cell cycle control and apoptosis and implications for glioma growth. <i>Journal of Neuro-Oncology</i> , 2001, 51, 219-229.	1.4	74
56	Wnt and Notch signaling govern self-renewal and differentiation in a subset of human glioblastoma stem cells. <i>Genes and Development</i> , 2019, 33, 498-510.	2.7	74
57	A C19MC-LIN28A-MYCN Oncogenic Circuit Driven by Hijacked Super-enhancers Is a Distinct Therapeutic Vulnerability in ETMRs: A Lethal Brain Tumor. <i>Cancer Cell</i> , 2019, 36, 51-67.e7.	7.7	69
58	Brain tumour stem cells: the undercurrents of human brain cancer and their relationship to neural stem cells. <i>Philosophical Transactions of the Royal Society B: Biological Sciences</i> , 2008, 363, 139-152.	1.8	67
59	Cell Surface Profiling Using High-Throughput Flow Cytometry: A Platform for Biomarker Discovery and Analysis of Cellular Heterogeneity. <i>PLoS ONE</i> , 2014, 9, e105602.	1.1	65
60	Outcomes of BRAF V600E Pediatric Gliomas Treated With Targeted BRAF Inhibition. <i>JCO Precision Oncology</i> , 2020, 4, 561-571.	1.5	62
61	Retinoic acid and the cyclin dependent kinase inhibitors synergistically alter proliferation and morphology of U343 astrocytoma cells. <i>Oncogene</i> , 1997, 15, 2037-2048.	2.6	61
62	Pediatric awake craniotomy and intra-operative stimulation mapping. <i>Journal of Clinical Neuroscience</i> , 2014, 21, 1891-1894.	0.8	60
63	Separating Stem Cells by Flow Cytometry: Reducing Variability for Solid Tissues. <i>Cell Stem Cell</i> , 2009, 5, 579-583.	5.2	58
64	Verotoxins inhibit the growth of and induce apoptosis in human astrocytoma cells. <i>Journal of Neuro-Oncology</i> , 1998, 40, 137-150.	1.4	56
65	Engineering Genetic Predisposition in Human Neuroepithelial Stem Cells Recapitulates Medulloblastoma Tumorigenesis. <i>Cell Stem Cell</i> , 2019, 25, 433-446.e7.	5.2	56
66	ATM Regulates 3-Methylpurine-DNA Glycosylase and Promotes Therapeutic Resistance to Alkylating Agents. <i>Cancer Discovery</i> , 2014, 4, 1198-1213.	7.7	55
67	Poly-ADP-Ribose Polymerase as a Therapeutic Target in Pediatric Diffuse Intrinsic Pontine Glioma and Pediatric High-Grade Astrocytoma. <i>Molecular Cancer Therapeutics</i> , 2015, 14, 2560-2568.	1.9	55
68	Breath-Hold Blood Oxygen Level-Dependent MRI: A Tool for the Assessment of Cerebrovascular Reserve in Children with Moyamoya Disease. <i>American Journal of Neuroradiology</i> , 2018, 39, 1717-1723.	1.2	55
69	Brain Tumor Stem Cells Remain in Play. <i>Journal of Clinical Oncology</i> , 2017, 35, 2428-2431.	0.8	54
70	Brain Tumor Stem Cells: Identification and Concepts. <i>Neurosurgery Clinics of North America</i> , 2007, 18, 31-38.	0.8	53
71	Genomic predictors of response to PD-1 inhibition in children with germline DNA replication repair deficiency. <i>Nature Medicine</i> , 2022, 28, 125-135.	15.2	53
72	High-resolution structural genomics reveals new therapeutic vulnerabilities in glioblastoma. <i>Genome Research</i> , 2019, 29, 1211-1222.	2.4	52

#	ARTICLE	IF	CITATIONS
73	Invitation to a second round. <i>Nature</i> , 2010, 466, 40-41.	13.7	49
74	Survival and functional outcomes of molecularly defined childhood posterior fossa ependymoma: Cure at a cost. <i>Cancer</i> , 2019, 125, 1867-1876.	2.0	49
75	The transcriptional landscape of Shh medulloblastoma. <i>Nature Communications</i> , 2021, 12, 1749.	5.8	47
76	The E2F-family proteins induce distinct cell cycle regulatory factors in p16-arrested, U343 astrocytoma cells. <i>Oncogene</i> , 1998, 17, 867-876.	2.6	46
77	Preclinical target validation using patient-derived cells. <i>Nature Reviews Drug Discovery</i> , 2015, 14, 149-150.	21.5	46
78	Single-cell chromatin accessibility profiling of glioblastoma identifies an invasive cancer stem cell population associated with lower survival. <i>ELife</i> , 2021, 10, .	2.8	45
79	Glioma migration: clues from the biology of neural progenitor cells and embryonic CNS cell migration. , 2001, 53, 203-212.		42
80	ID1 Is Critical for Tumorigenesis and Regulates Chemoresistance in Glioblastoma. <i>Cancer Research</i> , 2019, 79, 4057-4071.	0.4	39
81	Dual Regulatory Functions of SUFU and Targetome of GLI2 in SHH Subgroup Medulloblastoma. <i>Developmental Cell</i> , 2019, 48, 167-183.e5.	3.1	39
82	Clinical impact of combined epigenetic and molecular analysis of pediatric low-grade gliomas. <i>Neuro-Oncology</i> , 2020, 22, 1474-1483.	0.6	39
83	The white matter is a pro-differentiative niche for glioblastoma. <i>Nature Communications</i> , 2021, 12, 2184.	5.8	37
84	Medulloblastoma Arises from the Persistence of a Rare and Transient Sox2+ Granule Neuron Precursor. <i>Cell Reports</i> , 2020, 31, 107511.	2.9	35
85	Cyclin and Cyclin-Dependent Kinase Expression in Human Astrocytoma Cell Lines. <i>Journal of Neuropathology and Experimental Neurology</i> , 1997, 56, 291-300.	0.9	34
86	Craniospinal irradiation as part of re-irradiation for children with recurrent intracranial ependymoma. <i>Neuro-Oncology</i> , 2019, 21, 547-557.	0.6	32
87	Management and outcome of chordomas in the pediatric population: The Hospital for Sick Children experience and review of the literature. <i>Journal of Clinical Neuroscience</i> , 2016, 34, 169-176.	0.8	29
88	New drugs for brain tumors? Insights from chemical probing of neural stem cells. <i>Medical Hypotheses</i> , 2009, 72, 683-687.	0.8	28
89	Patterns of Cerebral Ischemia in Children With Moyamoya. <i>Pediatric Neurology</i> , 2015, 52, 65-72.	1.0	28
90	Intratumoral Genetic and Functional Heterogeneity in Pediatric Glioblastoma. <i>Cancer Research</i> , 2019, 79, 2111-2123.	0.4	28

#	ARTICLE	IF	CITATIONS
91	Gastrointestinal transcription factors drive lineage-specific developmental programs in organ specification and cancer. <i>Science Advances</i> , 2019, 5, eaax8898.	4.7	26
92	Factors Contributing to Major Neurological Complications From Vein of Galen Malformation Embolization. <i>JAMA Neurology</i> , 2020, 77, 992.	4.5	26
93	Identification of alsterpaullone as a novel small molecule inhibitor to target group 3 medulloblastoma. <i>Oncotarget</i> , 2015, 6, 21718-21729.	0.8	26
94	Selective Calcium Sensitivity in Immature Glioma Cancer Stem Cells. <i>PLoS ONE</i> , 2014, 9, e115698.	1.1	23
95	Bmi1 and Cell of Origin Determinants of Brain Tumor Phenotype. <i>Cancer Cell</i> , 2007, 12, 295-297.	7.7	22
96	Brain Cancer Stem Cells: A Level Playing Field. <i>Cell Stem Cell</i> , 2009, 5, 468-469.	5.2	20
97	MicroRNAs and Parallel Stem Cell Lives. <i>Cell</i> , 2009, 138, 423-424.	13.5	18
98	Distinct Clinical and Radiographic Phenotypes in Pediatric Patients With Moyamoya. <i>Pediatric Neurology</i> , 2021, 120, 18-26.	1.0	18
99	Brain tumor stem cells. <i>Biology of Blood and Marrow Transplantation</i> , 2005, 11, 12-13.	2.0	16
100	Association Between Prolonged Seizures and Malignant Middle Cerebral Artery Infarction in Children With Acute Ischemic Stroke. <i>Pediatric Neurology</i> , 2016, 64, 44-51.	1.0	16
101	Expression of stromelysin 1 in human astrocytoma cell lines. <i>Journal of Neuro-Oncology</i> , 1996, 30, 181-8.	1.4	15
102	Cip/Kip cell-cycle inhibitors: a neuro-oncological perspective. <i>Journal of Neuro-Oncology</i> , 2001, 51, 205-218.	1.4	15
103	THE HISTORY OF NEUROSURGERY AT THE HOSPITAL FOR SICK CHILDREN IN TORONTO. <i>Neurosurgery</i> , 2007, 61, 612-625.	0.6	15
104	Norrin mediates tumor-promoting and -suppressive effects in glioblastoma via Notch and Wnt. <i>Journal of Clinical Investigation</i> , 2020, 130, 3069-3086.	3.9	15
105	Treatment Strategies and Related Outcomes for Brain Arteriovenous Malformations in Children: A Systematic Review and Meta-Analysis. <i>American Journal of Roentgenology</i> , 2020, 215, 472-487.	1.0	14
106	Pan-cancer analysis of non-coding transcripts reveals the prognostic onco-lncRNA HOXA10-AS in gliomas. <i>Cell Reports</i> , 2021, 37, 109873.	2.9	13
107	Predicting Ischemic Risk Using Blood Oxygen Level-Dependent MRI in Children with Moyamoya. <i>American Journal of Neuroradiology</i> , 2020, 41, 160-166.	1.2	12
108	Cancer's source in the peripheral nervous system. <i>Nature Medicine</i> , 2008, 14, 373-375.	15.2	10

#	ARTICLE	IF	CITATIONS
109	Trametinib Toxicities in Patients With Low-grade Gliomas and Diabetes Insipidus: Related Findings?. <i>Journal of Pediatric Hematology/Oncology</i> , 2020, 42, e248-e250.	0.3	10
110	Single-cell chromatin profiling of the primitive gut tube reveals regulatory dynamics underlying lineage fate decisions. <i>Nature Communications</i> , 2022, 13, .	5.8	10
111	Diffuse intrinsic pontine glioma ventricular peritoneal shunt metastasis: a case report and literature review. <i>Child's Nervous System</i> , 2019, 35, 861-864.	0.6	9
112	The DEAD-box helicase DDX56 is a conserved stemness regulator in normal and cancer stem cells. <i>Cell Reports</i> , 2021, 34, 108903.	2.9	9
113	Translating Basic Science Discoveries into Improved Outcomes for Glioblastoma. <i>Clinical Cancer Research</i> , 2020, 26, 2457-2460.	3.2	8
114	Deep venous communication in vein of Galen malformations: incidence, Imaging, and Implications for treatment. <i>Journal of NeuroInterventional Surgery</i> , 2021, 13, 290-293.	2.0	8
115	Unruptured intracranial aneurysms in children: 18 years' experience in a tertiary care pediatric institution. <i>Journal of Neurosurgery: Pediatrics</i> , 2019, 24, 184-189.	0.8	8
116	Paediatric atypical choroid plexus papilloma: is adjuvant therapy necessary?. <i>Journal of Neuro-Oncology</i> , 2021, 155, 63-70.	1.4	6
117	Improving long-term outcomes in pediatric torcular dural sinus malformations with embolization and anticoagulation: a retrospective review of The Hospital for Sick Children experience. <i>Journal of Neurosurgery: Pediatrics</i> , 2021, 28, 469-475.	0.8	6
118	Re-evaluating surgery and re-irradiation for locally recurrent pediatric ependymoma – a multi-institutional study. <i>Neuro-Oncology Advances</i> , 2021, 3, vdab158.	0.4	5
119	Is jugular bulb stenosis in vein of Galen aneurysmal malformation associated with bony remodeling of the jugular foramina?. <i>Journal of Neurosurgery: Pediatrics</i> , 2016, 18, 92-96.	0.8	4
120	Intracranial artery to artery spontaneous revascularization in a child. <i>Child's Nervous System</i> , 2017, 33, 2035-2038.	0.6	4
121	Locations, associations and temporal evolution of intracranial arterial infundibular dilatations in children. <i>Journal of NeuroInterventional Surgery</i> , 2020, 12, 495-498.	2.0	4
122	Fractional Flow on TOF-MRA as a Measure of Stroke Risk in Children with Intracranial Arterial Stenosis. <i>American Journal of Neuroradiology</i> , 2020, 41, 535-541.	1.2	4
123	Building the ecosystem for pediatric neuro-oncology care in Pakistan: Results of a 7-year long twinning program between Canada and Pakistan. <i>Pediatric Blood and Cancer</i> , 2022, 69, e29726.	0.8	4
124	Global chromatin architecture defines functional cancer hierarchies. <i>Cell Cycle</i> , 2016, 15, 2093-2094.	1.3	3
125	Delayed Chronic Subdural Hematoma after Total Cranial Vault Reconstruction for Sagittal Synostosis. <i>Pediatric Neurosurgery</i> , 2018, 53, 200-204.	0.4	3
126	Clinical and Angioarchitectural Features of Hemorrhagic Brain Arterio-Venous Malformations in Adults and Children: Contrasts and Implications on Outcome. <i>Neurosurgery</i> , 2021, 89, 645-652.	0.6	3

#	ARTICLE	IF	CITATIONS
127	Fronto-Parietal and White Matter Haemodynamics Predict Cognitive Outcome in Children with Moyamoya Independent of Stroke. <i>Translational Stroke Research</i> , 2022, 13, 757-773.	2.3	3
128	Long Vascular Sheaths for Transfemoral Neuroendovascular Procedures in Children. <i>Neurointervention</i> , 2021, 16, 149-157.	0.5	2
129	Neurovascular Manifestations in Pediatric Patients With Hereditary Haemorrhagic Telangiectasia. <i>Pediatric Neurology</i> , 2022, 129, 24-30.	1.0	2
130	Successful management of symptomatic hydrocephalus using a temporary external ventricular drain with or without endoscopic third ventriculostomy in pediatric patients with germinoma. <i>Journal of Neurosurgery</i> , 2021, , 1-6.	0.9	2
131	GCT-22. OUTCOMES OF CHILDREN WITH LOCALIZED AND METASTATIC GERMINOMA TREATED WITH CHEMOTHERAPY FOLLOWED BY RADIATION THERAPY WITHOUT PRIMARY TUMOR BOOST. <i>Neuro-Oncology</i> , 2022, 24, i59-i59.	0.6	2
132	Making a commitment: neurons refuse cancer's advances. <i>Nature Neuroscience</i> , 2019, 22, 507-508.	7.1	1
133	Three-Dimensional Computed Tomography Reconstruction Unmasks Shunt Disconnection in a Child. <i>Canadian Journal of Neurological Sciences</i> , 2020, 47, 826-827.	0.3	1
134	Surgical management of pediatric rolandic arteriovenous malformations: a single-center case series. <i>Journal of Neurosurgery: Pediatrics</i> , 2021, 27, 62-68.	0.8	1
135	IMMU-18. FAVORABLE OUTCOME IN REPLICATION REPAIR DEFICIENT HYPERMUTANT BRAIN TUMORS TO IMMUNE CHECKPOINT INHIBITION: AN INTERNATIONAL RRD CONSORTIUM REGISTRY STUDY. <i>Neuro-Oncology</i> , 2020, 22, iii363-iii363.	0.6	1
136	Current Concepts in Neuro-Oncology: The Cell Cycle-A Review. <i>Neurosurgery</i> , 1997, , .	0.6	0
137	LG-66CLINICAL AND TREATMENT FACTORS DETERMINING LONG-TERM OUTCOMES FOR ADULT SURVIVORS OF CHILDHOOD LOW-GRADE GLIOMA: A POPULATION-BASED STUDY. <i>Neuro-Oncology</i> , 2016, 18, iii94.1-iii94.	0.6	0
138	LGG-10. EPIGENETIC/GENETIC/MORPHOLOGIC ANALYSES REVEAL CLINICAL/PROGNOSTIC INSIGHT OF PEDIATRIC LOW GRADE GLIOMAS. <i>Neuro-Oncology</i> , 2018, 20, i106-i106.	0.6	0
139	HGG-17. TUMOR MUTATIONAL BURDEN ANALYSIS OF PEDIATRIC TUMORS PROVIDES A DIAGNOSTIC TOOL FOR GERMLINE REPLICATION REPAIR DEFICIENCY AND PREDICT RESPONSE TO IMMUNE CHECKPOINT INHIBITION. <i>Neuro-Oncology</i> , 2018, 20, i92-i92.	0.6	0
140	LGG-59. REMARKABLE OBJECTIVE RESPONSE AND FAVORABLE SURVIVAL FOR BRAF-V600E CHILDHOOD LOW-GRADE GLIOMAS TO BRAF INHIBITORS COMPARED CONVENTIONAL CHEMOTHERAPY. <i>Neuro-Oncology</i> , 2018, 20, i117-i117.	0.6	0
141	IMMU-20. IMMUNE AND TUMOR BIOMARKERS OF OUTCOME IN REPLICATION REPAIR DEFICIENT BRAIN TUMORS TREATED WITH IMMUNE CHECKPOINT INHIBITORS: UPDATES FROM THE INTERNATIONAL REPLICATION REPAIR DEFICIENCY CONSORTIUM. <i>Neuro-Oncology</i> , 2019, 21, ii96-ii97.	0.6	0
142	PDCT-08. SUPERIOR OUTCOME FOR BRAF V600E PEDIATRIC GLIOMAS TREATED WITH TARGETED BRAF INHIBITION. <i>Neuro-Oncology</i> , 2019, 21, vi184-vi185.	0.6	0
143	LGG-16. PREDICTORS OF OUTCOME IN BRAF-V600E PEDIATRIC GLIOMAS TREATED WITH BRAF INHIBITORS: A REPORT FROM THE PLGG TASKFORCE. <i>Neuro-Oncology</i> , 2019, 21, ii102-ii102.	0.6	0
144	ETMR-22. TITLE: DEFINING THE CLINICAL AND PROGNOSTIC LANDSCAPE OF EMBRYONAL TUMORS WITH MULTI-LAYERED ROSETTES (ETMRs), A RARE BRAIN TUMOR REGISTRY (RBTC) STUDY. <i>Neuro-Oncology</i> , 2020, 22, iii327-iii328.	0.6	0

#	ARTICLE	IF	CITATIONS
145	Pediatric multicompartmental trigeminal schwannoma: illustrative case. <i>Journal of Neurosurgery Case Lessons</i> , 2021, 1, .	0.1	0
146	Cerebral Sinovenous Thrombosis Post Head Injury - 10 Year Experience in Children.. <i>Blood</i> , 2005, 106, 4132-4132.	0.6	0
147	Molecular alterations to predict survival and response to chemotherapy of pediatric low-grade glioma.. <i>Journal of Clinical Oncology</i> , 2017, 35, 10503-10503.	0.8	0
148	The Functional Genomic Circuitry of Human Glioblastoma Stem Cells. <i>SSRN Electronic Journal</i> , 0, , .	0.4	0
149	RARE-09. PRESERVATION OF ENDOCRINE FUNCTION AFTER OMMAYA RESERVOIR INSERTION IN CHILDREN WITH CYSTIC CRANIOPHARYNGIOMA. <i>Neuro-Oncology</i> , 2020, 22, iii443-iii443.	0.6	0
150	LGG-55. OUTCOME OF BRAF V600E PEDIATRIC GLIOMAS TREATED WITH TARGETED BRAF INHIBITION. <i>Neuro-Oncology</i> , 2020, 22, iii377-iii377.	0.6	0
151	EPCO-22. INHERITED POLYMORPHISM IN CHROMOSOME 8Q24 COOPERATES WITH MUTANT IDH1, Trp53 AND ATRX LOSS TO INDUCE LOW-GRADE GLIOMA. <i>Neuro-Oncology</i> , 2021, 23, vi6-vi6.	0.6	0
152	STEM-26. BLOOD-TUMOR BARRIER IS COMPOSED OF MECHANOSENSING TUMOR CELLS THAT MASK THERAPEUTIC VULNERABILITY. <i>Neuro-Oncology</i> , 2021, 23, vi26-vi26.	0.6	0
153	TMOD-18. DIRECT IN VIVO CRISPR SCREEN IDENTIFIES COOPERATING TUMOR SUPPRESSORS THAT DRIVE PROGRESSION OF IDH1-MUTANT LOW-GRADE GLIOMA TO AGGRESSIVE GLIOBLASTOMA. <i>Neuro-Oncology</i> , 2021, 23, vi219-vi219.	0.6	0
154	STEM-29. THE HISTONE VARIANT macroH2A2 ORCHESTRATES AN ACTIONABLE CHROMATIN PROGRAM OF STEMNESS IN GLIOBLASTOMA. <i>Neuro-Oncology</i> , 2020, 22, ii202-ii202.	0.6	0
155	264. A 20-year Study of Intracranial Pyogenic Complications of Sinusitis in Children. <i>Open Forum Infectious Diseases</i> , 2021, 8, S238-S238.	0.4	0
156	LGG-41. The clinical and molecular landscape of gliomas in adolescents and young adults. <i>Neuro-Oncology</i> , 2022, 24, i97-i97.	0.6	0
157	Abstract LB188: Identification of intrinsic molecular vulnerabilities in inherited and treatment-related hypermutant patient-derived glioma cell line models. <i>Cancer Research</i> , 2022, 82, LB188-LB188.	0.4	0